Samsung Bioepis Signs Exclusive Supply Deal in Brazil's Rare-Disease Government Programme
Samsung Epis Holdings said its unit Samsung Bioepis signed an exclusive supply agreement for SB12 under a Brazilian government rare-disease treatment programme.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Samsung Epis Holdings said its unit Samsung Bioepis has entered into an exclusive supply agreement under a Brazilian government programme for rare-disease treatment. The product involved is SB12, a biosimilar to Soliris.
The information comes from the company's statement, as reported by Reuters. The statement did not disclose the terms of the contract or its financial value.
why it matters
The news concerns a narrow niche of the biosimilar market, so its direct impact on broader markets is limited. Still, such government contracts show that large biosimilar makers are gaining access to public programmes in emerging markets.
tags
instruments
sources
- Samsung Epis Holdings Says Unit Samsung Bioepis Entered Into Exclusive Supply Agreement Under Brazilian Government Programme For Rare-Disease Treatment — Reuters, 21 October 2026 at 01:50 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗